Company-reported development
HairClone reported in March 2026, with its page updated in July, that a cell-manufacturing facility in a private hospital in Guatemala City had become operational. It said the manufacturing process had been transferred from the United Kingdom and validated.
On 30 September 2026, the company stated that cells expanded from banked follicle tissue had begun to be injected into an early cohort of patients. It also said preliminary results were intended for presentation at the ISHRS meeting in October.
Information available for independent assessment
The September announcement does not provide a registered protocol, participant flow, predefined endpoints, comparator design, adverse-event data or treatment outcomes. A planned conference presentation is not itself evidence of efficacy.
The reported start of injections is a meaningful operational milestone, but it remains a company account. Treatment availability through a partner network does not establish efficacy or broad regulatory approval.
Evidence classification
HairClone is classified as early clinical evaluation on the basis of the company’s account. The classification will be revised when traceable protocol details, patient data or independent publications provide further evidence.